Systemic lupus erythematosus (SLE) is characterized by increased cardiovascular morbidity and mortality. SLE patients have increased prevalence of subclinical atherosclerosis, although the mechanisms of this observation remain unclear. Considering the emerging role of monocytes in atherosclerosis, we aimed to investigate the relationship between subclinical atherosclerosis, endothelial dysfunction and the phenotype of peripheral blood monocytes in SLE patients.
Methods
We characterized the phenotype of monocyte subsets defined by the expression of CD14 and CD16 in 42 patients with SLE and 42 non-SLE controls. Using ultrasonography, intima-media thickness (IMT) of carotid arteries and brachial artery flow-mediated dilation (FMD) as well as nitroglycerin-induced dilation (NMD) were assessed.
Results
Patients with SLE had significantly, but only modestly, increased IMT when compared with non-SLE controls (median (25th/75th percentile) 0.65 (0.60/0.71) mm vs 0.60 (0.56/0.68) mm; p < 0.05). Importantly, in spite of early atherosclerotic complications in the studied SLE group, marked endothelial dysfunction was observed. CD14dimCD16+proinflammatory cell subpopulation was positively correlated with IMT in SLE patients. This phenomenon was not observed in control individuals. Interestingly, endothelial dysfunction assessed by FMD was not correlated with any of the studied monocyte subsets.
Conclusions
Our observations suggest that CD14dimCD16+monocytes are associated with subclinical atherosclerosis in SLE, although the mechanism appears to be independent of endothelial dysfunction.
DoriaAIaccarinoLGhirardelloA. Long-term prognosis and causes of death in systemic lupus erythematosus. Am J Med2006; 119: 700–706.
2.
CrowsonCSLiaoKPDavisJM3rd. Rheumatoid arthritis and cardiovascular disease. Am Heart J2013; 166: 622–628.e621.
3.
ManziSMeilahnENRairieJE. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: Comparison with the Framingham Study. Am J Epidemiol1997; 145: 408–415.
4.
RomanMJShankerBADavisA. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med2003; 349: 2399–2406.
5.
WilkGOsmendaGMatusikP. Endothelial function assessment in atherosclerosis: Comparison of brachial artery flow-mediated vasodilation and peripheral arterial tonometry. Pol Arch Med Wewn2013; 123: 443–452.
6.
TellesRWLannaCCSousaAJ. Progression of carotid atherosclerosis in patients with systemic lupus erythematosus. Clin Rheumatol2013; 32: 1293–1300.
7.
AmmiratiEBozzoloEPContriR. Cardiometabolic and immune factors associated with increased common carotid artery intima-media thickness and cardiovascular disease in patients with systemic lupus erythematosus. Nutr Metab Cardiovasc Dis2014; 24: 751–759.
8.
GustafssonJTSvenungssonE. Definitions of and contributions to cardiovascular disease in systemic lupus erythematosus. Autoimmunity2014; 47: 67–76.
9.
McMahonMSkaggsBJSahakianL. High plasma leptin levels confer increased risk of atherosclerosis in women with systemic lupus erythematosus, and are associated with inflammatory oxidised lipids. Ann Rheum Dis2011; 70: 1619–1624.
10.
TenediosFErkanDLockshinMD. Cardiac involvement in the antiphospholipid syndrome. Lupus2005; 14: 691–696.
11.
CojocaruIMCojocaruMButnaruLMiuGTanasescuR. Study of anti-endothelial cell antibodies in SLE patients with acute ischemic stroke. Rom J Intern Med2010; 48: 173–177.
12.
SteinbachFHenkeFKrauseBThieleBBurmesterGRHiepeF. Monocytes from systemic lupus erythematous patients are severely altered in phenotype and lineage flexibility. Ann Rheum Dis2000; 59: 283–288.
13.
WongKLTaiJJWongWC. Gene expression profiling reveals the defining features of the classical, intermediate, and nonclassical human monocyte subsets. Blood2011; 118: e16–e31.
14.
HeineGHUlrichCSeibertE. CD14(++)CD16+ monocytes but not total monocyte numbers predict cardiovascular events in dialysis patients. Kidney Int2008; 73: 622–629.
15.
ShantsilaETappLDWrigleyBJ. Monocyte subsets in coronary artery disease and their associations with markers of inflammation and fibrinolysis. Atherosclerosis2014; 234: 4–10.
16.
SchlittAHeineGHBlankenbergS. CD14+CD16+ monocytes in coronary artery disease and their relationship to serum TNF-alpha levels. Thromb Haemost2004; 92: 419–424.
17.
ShantsilaELipGY. Monocyte diversity in myocardial infarction. J Am Coll Cardiol2009; 54: 139–142.
18.
FrantzSHofmannUFraccarolloD. Monocytes/macrophages prevent healing defects and left ventricular thrombus formation after myocardial infarction. FASEB J2013; 27: 871–881.
19.
van der LaanAMHirschARobbersLF. A proinflammatory monocyte response is associated with myocardial injury and impaired functional outcome in patients with ST-segment elevation myocardial infarction: Monocytes and myocardial infarction. Am Heart J2012; 163: 57–65.e52.
20.
SurdackiASulickaJKorkoszM. Blood monocyte heterogeneity and markers of endothelial activation in ankylosing spondylitis. J Rheumatol2014; 41: 481–489.
21.
MikołajczykTPSkibaDBatkoB. Characterization of the impairment of the uptake of apoptotic polymorphonuclear cells by monocyte subpopulations in systemic lupus erythematosus. Lupus2014; 23: 1358–1369.
22.
BombardierCGladmanDDUrowitzMBCaronDChangCH. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum1992; 35: 630–640.
23.
SulickaJSurdackiAMikołajczykT. Elevated markers of inflammation and endothelial activation and increased counts of intermediate monocytes in adult survivors of childhood acute lymphoblastic leukemia. Immunobiology2013; 218: 810–816.
24.
BartelsCMBuhrKAGoldbergJW. Mortality and cardiovascular burden of systemic lupus erythematosus in a US population-based cohort. J Rheumatol2014; 41: 680–687.
25.
ContiFSpinelliFRAlessandriC. Subclinical atherosclerosis in systemic lupus erythematosus and antiphospholipid syndrome: Focus on beta2GPI-specific T cell response. Arterioscler Thromb Vasc Biol2014; 34: 661–668.
26.
MatusikPGuzikBWeberCGuzikTJ. Do we know enough about the immune pathogenesis of acute coronary syndromes to improve clinical practice?Thromb Haemost2012; 108: 443–456.
27.
KissESolteszPDerH. Reduced flow-mediated vasodilation as a marker for cardiovascular complications in lupus patients. J Autoimmun2006; 27: 211–217.
28.
LimaDSSatoEILimaVCMirandaFJrHattaFH. Brachial endothelial function is impaired in patients with systemic lupus erythematosus. J Rheumatol2002; 29: 292–297.
29.
El-MagadmiMBodillHAhmadY. Systemic lupus erythematosus: An independent risk factor for endothelial dysfunction in women. Circulation2004; 110: 399–404.
30.
InabaYChenJABergmannSR. Prediction of future cardiovascular outcomes by flow-mediated vasodilatation of brachial artery: A meta-analysis. Int J Cardiovasc Imaging2010; 26: 631–640.
31.
KaradagOCalguneriMAtalarE. Novel cardiovascular risk factors and cardiac event predictors in female inactive systemic lupus erythematosus patients. Clin Rheumatol2007; 26: 695–699.
32.
HristovMLeyendeckerTSchuhmannC. Circulating monocyte subsets and cardiovascular risk factors in coronary artery disease. Thromb Haemost2010; 104: 412–414.
33.
HanssonGK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med2005; 352: 1685–1695.
34.
MikołajczykTPSkrzeczyńska-MoncznikJEZarebskiMA. Interaction of human peripheral blood monocytes with apoptotic polymorphonuclear cells. Immunology2009; 128: 103–113.
35.
Ziegler-HeitbrockL. The CD14+ CD16+ blood monocytes: Their role in infection and inflammation. J Leukoc Biol2007; 81: 584–592.
36.
FranzeckFCHofDSpeschaRD. Expression of the aging gene p66Shc is increased in peripheral blood monocytes of patients with acute coronary syndrome but not with stable coronary artery disease. Atherosclerosis2012; 220: 282–286.
37.
PaneniFCostantinoSCastelloL. Targeting prolyl-isomerase Pin1 prevents mitochondrial oxidative stress and vascular dysfunction: Insights in patients with diabetes. Eur Heart J2015; 36: 817–828.
38.
RogacevKSUlrichCBlömerL. Monocyte heterogeneity in obesity and subclinical atherosclerosis. Eur Heart J2010; 31: 369–376.
39.
RogacevKSSeilerSZawadaAM. CD14++CD16+ monocytes and cardiovascular outcome in patients with chronic kidney disease. Eur Heart J2011; 32: 84–92.
40.
KashiwagiMImanishiTTsujiokaH. Association of monocyte subsets with vulnerability characteristics of coronary plaques as assessed by 64-slice multidetector computed tomography in patients with stable angina pectoris. Atherosclerosis2010; 212: 171–176.
41.
UlrichCHeineGHGerhartMKKöhlerHGirndtM. Proinflammatory CD14+CD16+ monocytes are associated with subclinical atherosclerosis in renal transplant patients. Am J Transplant2008; 8: 103–110.
42.
RotheGHerrASStöhrJAbletshauserCWeidingerGSchmitzG. A more mature phenotype of blood mononuclear phagocytes is induced by fluvastatin treatment in hypercholesterolemic patients with coronary heart disease. Atherosclerosis1999; 144: 251–261.
43.
MosigSRennertKKrauseS. Different functions of monocyte subsets in familial hypercholesterolemia: Potential function of CD14+ CD16+ monocytes in detoxification of oxidized LDL. FASEB J2009; 23: 866–874.
44.
Ziegler-HeitbrockHWFingerleGStröbelM. The novel subset of CD14+/CD16+ blood monocytes exhibits features of tissue macrophages. Eur J Immunol1993; 23: 2053–2058.
45.
FrankenbergerMSternsdorfTPechumerHPforteAZiegler-HeitbrockHW. Differential cytokine expression in human blood monocyte subpopulations: A polymerase chain reaction analysis. Blood1996; 87: 373–377.
46.
YuanWDiMartinoSJRedechaPBIvashkivLBSalmonJE. Systemic lupus erythematosus monocytes are less responsive to interleukin-10 in the presence of immune complexes. Arthritis Rheum2011; 63: 212–218.
47.
BanaiSFinkelsteinAAlmagorY. Targeted anti-inflammatory systemic therapy for restenosis: The Biorest Liposomal Alendronate with Stenting sTudy (BLAST)-a double blind, randomized clinical trial. Am Heart J2013; 165: 234–240.e231.
48.
EverettBMPradhanADSolomonDH. Rationale and design of the Cardiovascular Inflammation Reduction Trial: A test of the inflammatory hypothesis of atherothrombosis. Am Heart J2013; 166: 199–207.e115.
